

**STRIDES PHARMA INTERNATIONAL LIMITED**  
**BALANCE SHEET AS AT MARCH 31, 2019**

	Amount in USD 31-Mar-19	Amount in USD 31-Mar-18
<b>A ASSETS</b>		
<b>I Current assets</b>		
(a) Financial assets		
(i) Cash and cash equivalents	1      563,699	254,918
(ii) Other financial assets	2      17,276,404	23,435,794
(b) Other current assets	3      139,005	152,730
<b>Total current assets</b>	<b>17,979,108</b>	<b>23,843,442</b>
<b>TOTAL ASSETS</b>	<b>17,979,108</b>	<b>23,843,442</b>
<b>B EQUITY AND LIABILITIES</b>		
<b>I Equity</b>		
(a) Equity share capital	4      438,000	438,000
(b) Other equity	5      13,341,102	18,701,934
<b>Total Equity</b>	<b>13,779,102</b>	<b>19,139,934</b>
<b>II Liabilities</b>		
<b>1 Current liabilities</b>		
(a) Financial liabilities		
(i) Trade payables	6      433,443	579,678
(b) Current income tax liabilities	7      3,766,563	4,123,830
<b>Total current liabilities</b>	<b>4,200,006</b>	<b>4,703,509</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>17,979,109</b>	<b>23,843,442</b>

**STRIDES PHARMA INTERNATIONAL LIMITED**  
**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2019**

		Amount in USD	
Particulars	Note No.	31-Mar-19	31-Mar-18
<b>1</b> Revenue from operations	8	-	149,963
<b>2</b> Other Income	9	523,890	3,369,238
<b>3 Total Revenue (1+2)</b>		<b><u>523,890</u></b>	<b><u>3,519,201</u></b>
<b>4 Expenses</b>			
(a) Finance costs	10	2,693	218,295
(b) Other expenses	11	2,144,220	1,210,029
<b>Total expenses</b>		<b><u>2,146,914</u></b>	<b><u>1,428,324</u></b>
<b>5 Profit / (Loss) before exceptional items and taxes (3-4)</b>		<b><u>(1,623,023)</u></b>	<b><u>2,090,877</u></b>
<b>6</b> Exceptional Item		(4,082,825)	173,098
<b>7 Profit / (Loss) before taxes (5+6)</b>		<b><u>(5,705,848)</u></b>	<b><u>2,263,975</u></b>
<b>8 Tax Expense:</b>			
(1) Current tax		(345,017)	50,417
(2) Deferred tax		-	-
Total tax expenses		<u>(345,017)</u>	<u>50,417</u>
<b>9 Profit / (Loss) for the year after tax</b>		<b><u>(5,360,831)</u></b>	<b><u>2,213,558</u></b>

**STRIDES PHARMA INTERNATIONAL LIMITED**  
**STATEMENT OF CHANGES IN EQUITY**  
**FOR THE YEAR ENDED MARCH 31, 2019**

**(A) Equity share capital**

Particulars	Amount in USD
<b>Balance as at March 31, 2017</b>	<b>438,000</b>
Changes in equity share capital during the year	-
<b>Balance as at March 31, 2018</b>	<b>438,000</b>
Changes in equity share capital during the year	-
<b>Balance as at March 31, 2019</b>	<b>438,000</b>

**(B) Other equity**

Particulars	Share application money pending allotment	Securities Premium Account	Reserves and surplus	Items of other comprehensive income	Total
			Retained earnings	Re -measurement of the defined benefit liabilities / (assets)	
<b>Balance as at March 31, 2017</b>	-	715,093	55,720,503	-	56,435,595
Profit/loss for the year	-	-	2,213,558	-	2,213,558
Dividend (including tax on dividend)	-	-	(7,656,240)	-	(7,656,240)
Adjustments pertaining to Scheme of Merger	-	(32,290,980)	-	-	(32,290,980)
Other comprehensive income for the year (net of tax)	-	-	-	-	-
<b>Balance as at March 31, 2018</b>	-	(31,575,887)	50,277,821	-	18,701,934
Application money received during the year	-	-	-	-	-
Profit/loss for the year	-	-	(5,360,831)	-	(5,360,831)
Other comprehensive income for the year (net of tax)	-	-	-	-	-
<b>Balance as at March 31, 2019</b>	-	(31,575,887)	44,916,990	-	13,341,102

STRIDES PHARMA INTERNATIONAL LIMITED  
Notes forming part of financial statement

Note  
No.

1 Cash and cash equivalents		Amount in USD	
Particulars	31-Mar-19	31-Mar-18	
<b>Balances with banks:</b>			
In current accounts	563,699	254,918	
<b>Total</b>	<b>563,699</b>	<b>254,918</b>	
2 Other financial assets		Amount in USD	
Particulars	31-Mar-19	31-Mar-18	
Advances to related parties	17,276,404	23,435,794	
<b>Total</b>	<b>17,276,404</b>	<b>23,435,794</b>	
3 Other current assets		Amount in USD	
Particulars	31-Mar-19	31-Mar-18	
<b>Unsecured, considered good</b>			
Balances with government authorities:	139,005	152,730	
<b>Total</b>	<b>139,005</b>	<b>152,730</b>	
4 Share capital		Amount in USD	
Particulars	31-Mar-19	31-Mar-18	
<b>Issued, subscribed and fully paid-up</b>			
Equity share capital	438,000	438,000	
<b>Total</b>	<b>438,000</b>	<b>438,000</b>	
5 Reserves and surplus		Amount in USD	
Particulars	31-Mar-19	31-Mar-18	
<b>Securities premium account</b>			
Opening balance	(31,575,887)	715,093	
Add : Premium on shares issued during the year	-	-	
Add : Adjustment pertaining to Scheme of Merger	-	(32,290,980)	
<b>Closing balance</b>	<b>(31,575,887)</b>	<b>(31,575,887)</b>	
<b>Surplus in statement of profit and loss</b>			
Opening balance	50,277,821	55,720,503	
Add: Profit / (Loss) for the year	(5,360,831)	2,213,558	
Less: Equity dividend	-	7,656,240	
Less: Preference dividend	-	-	
<b>Closing balance</b>	<b>44,916,990</b>	<b>50,277,821</b>	
<b>Total</b>	<b>13,341,102</b>	<b>18,701,934</b>	
6 Trade payables		Amount in USD	
Particulars	31-Mar-19	31-Mar-18	
Trade payable	433,443	579,678	
<b>Total</b>	<b>433,443</b>	<b>579,678</b>	
7 Current Income tax liability		Amount in USD	
Particulars	31-Mar-19	31-Mar-18	
Provision for income tax (net of advance tax)	3,766,563	4,123,830	
<b>Total</b>	<b>3,766,563</b>	<b>4,123,830</b>	

**STRIDES PHARMA INTERNATIONAL LIMITED**  
**Notes forming part of financial statement**

Note

No.

8	Revenue from operations	Amount in USD	
		31-Mar-19	31-Mar-18
	Particulars		
	Sale licensing Income		149,963
	<b>Total</b>	-	<b>149,963</b>

9	Other Income	Amount in USD	
		31-Mar-19	31-Mar-18
	Particulars		
	Dividend received	-	3,132,312
	Interest Income	523,890	236,926
	<b>Total</b>	<b>523,890</b>	<b>3,369,238</b>

10	Finance cost	Amount in USD	
		31-Mar-19	31-Mar-18
	Particulars		
	Bank charges	2,693	218,295
	<b>Total</b>	<b>2,693</b>	<b>218,295</b>

11	Other expenses	Amount in USD	
		31-Mar-19	31-Mar-18
	Particulars		
	Director Sittina fees	1,872	-
	Conversion & processing charges	1,922,803	617,770
	Rates & Taxes	(4,908)	403
	Net loss on foreign currency transactions	12,195	350,075
	Professional fees	176,497	228,934
	Payment to Auditors - For Statutory Audit	35,760	12,847
	<b>Total</b>	<b>2,144,220</b>	<b>1,210,029</b>